11/17
08:06 am
kod
Kodiak Sciences (NASDAQ:KOD) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
Kodiak Sciences (NASDAQ:KOD) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
11/17
08:06 am
kod
Kodiak Sciences (NASDAQ:KOD) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Kodiak Sciences (NASDAQ:KOD) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
11/14
09:31 am
kod
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus [Yahoo! Finance]
Low
Report
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus [Yahoo! Finance]
11/12
05:56 pm
kod
Kodiak Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
High
Report
Kodiak Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/12
05:48 pm
kod
Kodiak Sciences to Present at Upcoming Investor Conferences
High
Report
Kodiak Sciences to Present at Upcoming Investor Conferences
11/11
08:08 am
kod
Kodiak Sciences (NASDAQ:KOD) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $24.00 price target on the stock, up previously from $5.00.
Medium
Report
Kodiak Sciences (NASDAQ:KOD) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $24.00 price target on the stock, up previously from $5.00.
11/5
07:00 am
kod
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Low
Report
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
10/24
08:06 am
kod
Kodiak Sciences (NASDAQ:KOD) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $24.00 price target on the stock, up previously from $15.00.
Low
Report
Kodiak Sciences (NASDAQ:KOD) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $24.00 price target on the stock, up previously from $15.00.
10/23
06:16 pm
kod
Kodiak Sciences (NASDAQ:KOD) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $40.00 price target on the stock.
Medium
Report
Kodiak Sciences (NASDAQ:KOD) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $40.00 price target on the stock.
10/6
10:23 am
kod
Kodiak Sciences (NASDAQ:KOD) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Kodiak Sciences (NASDAQ:KOD) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
9/25
08:06 am
kod
Kodiak Sciences (NASDAQ:KOD) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $17.00 price target on the stock, up previously from $7.00.
Medium
Report
Kodiak Sciences (NASDAQ:KOD) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $17.00 price target on the stock, up previously from $7.00.
9/22
11:03 am
kod
Kodiak Sciences (NASDAQ:KOD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.
High
Report
Kodiak Sciences (NASDAQ:KOD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.
9/15
07:14 am
kod
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) [Yahoo! Finance]
Low
Report
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) [Yahoo! Finance]
9/15
07:00 am
kod
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Low
Report
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)